PMID- 34765296
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20211113
IS  - 2156-6976 (Print)
IS  - 2156-6976 (Electronic)
IS  - 2156-6976 (Linking)
VI  - 11
IP  - 10
DP  - 2021
TI  - LncRNA NR2F2-AS1 induces epithelial-mesenchymal transition of non-small cell lung 
      cancer by modulating BVR/ATF-2 pathway via regulating miR-545-5p/c-Met axis.
PG  - 4844-4865
AB  - Non-small cell lung cancer (NSCLC) is one type of the most common cancers, which 
      results in the major death worldwide. This study focuses on the understanding of 
      the molecular mechanism of lncRNA NR2F2-AS1 and its regulation on 
      epithelial-mesenchymal transition (EMT) in the development of NSCLC. Expressions 
      of lncRNA NR2F2-AS1, miR-545-5p, c-Met, biliverdin reductase (BVR), ATF-2 and 
      EMT-related markers in NSCLC tissues and cells were measured by western blotting 
      and RT-qPCR assays. The impact of lncRNA NR2F2-AS1 and miR-545-5p on the cell 
      proliferation, migration, invasion and EMT were analyzed by CCK-8, colony 
      formation, wound healing and transwell assays. The interactions among lncRNA 
      NR2F2-AS1, miR-545-5p and c-Met predicted by bioinformatic analysis were 
      evaluated through dual luciferase reporter assay and fluorescence in situ 
      hybridization (FISH). After generating tumor xenografts, immunohistochemistry was 
      utilized to measure the expression of Ki-67 and EMT-related proteins in vivo. Our 
      results showed that lncRNA NR2F2-AS1, c-Met, BVR and ATF-2 were overexpressed 
      while miR-545-5p was silenced in NSCLC tissues and cells. Silencing of lncRNA 
      NR2F2-AS1 or upregulating miR-545-5p significantly inhibited the cell 
      proliferation, migration, invasion and EMT process. The EMT process could be 
      inhibited by suppressing c-Met/BVR/ATF-2 axis. The tumor xenograft experiments 
      demonstrated that the tumor growth and EMT process were significantly inhibited 
      by silencing lncRNA NR2F2-AS1 or overexpression of miR-545-5p in vivo. LncRNA 
      NR2F2-AS1 promoted the NSCLC development through suppressing miR-545-5p to 
      activate EMT process through c-Met/BVR/ATF-2 axis. Our study indicated that 
      lncRNA NR2F2-AS1 and miR-545-5p could be used as potential therapeutic targets to 
      improve NSCLC treatment.
CI  - AJCR Copyright (c) 2021.
FAU - Liu, Cheng
AU  - Liu C
AD  - Department of Thoracic Surgery, The Fourth Affiliated Hospital of Harbin Medical 
      University Harbin 150001, Heilongjiang Province, P. R. China.
FAU - Li, Qun-Gen
AU  - Li QG
AD  - Department of Cardiothoracic Surgery, Heilongjiang Provincial Hospital Affiliated 
      to Harbin Institute of Technology Harbin 150001, Heilongjiang Province, P. R. 
      China.
FAU - Zhou, Yang
AU  - Zhou Y
AD  - Department of Medical Oncology, Harbin Medical University Cancer Hospital Harbin 
      150081, Heilongjiang Province, P. R. China.
FAU - Cao, Ying-Yue
AU  - Cao YY
AD  - Department of Medical Oncology, Harbin Medical University Cancer Hospital Harbin 
      150081, Heilongjiang Province, P. R. China.
FAU - Wei, Zi-Xin
AU  - Wei ZX
AD  - Department of Medical Oncology, Harbin Medical University Cancer Hospital Harbin 
      150081, Heilongjiang Province, P. R. China.
FAU - Jin, Ying-Hua
AU  - Jin YH
AD  - Department of Medical Oncology, Harbin Medical University Cancer Hospital Harbin 
      150081, Heilongjiang Province, P. R. China.
FAU - Wang, Xin
AU  - Wang X
AD  - Department of Medical Oncology, Harbin Medical University Cancer Hospital Harbin 
      150081, Heilongjiang Province, P. R. China.
FAU - Chen, Ying-Ying
AU  - Chen YY
AD  - Department of Gastroenterology, The First Affiliated Hospital of Harbin Medical 
      University Harbin 150001, Heilongjiang Province, P. R. China.
FAU - Qi, Li
AU  - Qi L
AD  - Department of Radiation Oncology, The Second Affiliated Hospital of Harbin 
      Medical University Harbin 150086, Heilongjiang Province, P. R. China.
FAU - Geng, Jian-Xiong
AU  - Geng JX
AD  - Department of Medical Oncology, Harbin Medical University Cancer Hospital Harbin 
      150081, Heilongjiang Province, P. R. China.
FAU - Liu, Fang
AU  - Liu F
AD  - Department of Medical Oncology, Harbin Medical University Cancer Hospital Harbin 
      150081, Heilongjiang Province, P. R. China.
LA  - eng
PT  - Journal Article
DEP - 20211015
PL  - United States
TA  - Am J Cancer Res
JT  - American journal of cancer research
JID - 101549944
PMC - PMC8569365
OTO - NOTNLM
OT  - LncRNA NR2F2-AS1
OT  - MiR-545-5p
OT  - Non-small cell lung cancer
OT  - biliverdin reductase
OT  - c-Met
OT  - epithelial-mesenchymal transition
COIS- None.
EDAT- 2021/11/13 06:00
MHDA- 2021/11/13 06:01
PMCR- 2021/10/15
CRDT- 2021/11/12 07:04
PHST- 2020/11/12 00:00 [received]
PHST- 2021/09/09 00:00 [accepted]
PHST- 2021/11/12 07:04 [entrez]
PHST- 2021/11/13 06:00 [pubmed]
PHST- 2021/11/13 06:01 [medline]
PHST- 2021/10/15 00:00 [pmc-release]
PST - epublish
SO  - Am J Cancer Res. 2021 Oct 15;11(10):4844-4865. eCollection 2021.